T. Rowe Price Biotech ETF (TDNA)
24.57
-0.13
(-0.54%)
USD |
NASDAQ |
Oct 02, 16:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.55% | -0.02% | 9.826M | -- |
| Weighted Average Dividend Yield | Turnover Ratio (Generic) | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| -- | -- | -- |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide long-term capital appreciation. The Fund normally invests at least 80% of its net assets in the securities of biotechnology companies or those companies engaged in health care innovations, such as developing new and effective therapies to treat and cure disease through the use of living cells. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | T. Rowe Price |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of October 04, 2026.
Asset Allocation
| Type | % Net |
|---|---|
| Cash | -- |
| Stock | -- |
| Bond | -- |
| Convertible | -- |
| Preferred | -- |
| Other | -- |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide long-term capital appreciation. The Fund normally invests at least 80% of its net assets in the securities of biotechnology companies or those companies engaged in health care innovations, such as developing new and effective therapies to treat and cure disease through the use of living cells. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | T. Rowe Price |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |